![[Insightec in PR Newswire] Insightec broadcasts milestone of first sufferers enrolled within the pivotal LIBERATE medical trial (Liquid Biopsy with Low Depth Ultrasound in Mind Tumors)](https://blog.ourcrowd.com/wp-content/uploads/2017/09/PR_newswire.jpg "[Insightec in PR Newswire] Insightec broadcasts milestone of first sufferers enrolled within the pivotal LIBERATE medical trial (Liquid Biopsy with Low Depth Ultrasound in Mind Tumors)")
HAIFA, Israel & MIAMI, Dec. 15, 2022 /PRNewswire/ — Insightec, a world healthcare firm devoted to utilizing acoustic power to remodel affected person care, introduced at present the primary sufferers have enrolled within the pivotal LIBERATE medical trial (Liquid Biopsy with Low Depth Ultrasound in Mind Tumors). Enrollment in LIBERATE marks the beginning of a world effort to evaluate security and efficacy of utilizing Insightec’s targeted ultrasound (FUS) platform to briefly disrupt the blood mind barrier (BBB) to allow liquid biopsies in sufferers with glioblastoma, the most typical major malignant mind tumor in adults.
Learn extra right here.
